The Valley Desk

NCT02282020 · Interventional trial

Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments

Overall registry status Completed

Phase 3

Conditions Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov